Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

NACompletedINTERVENTIONAL
Enrollment

368

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Dermatitis, Atopic
Interventions
BIOLOGICAL

Fluzone® Intradermal Vaccine

A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.

BIOLOGICAL

Fluzone® (Intramuscular) vaccine

A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.

Trial Locations (5)

14642

University of Rochester Medical Center, Rochester

60611

Northwestern University, Chicago

80206

National Jewish Health, Denver

97239

Oregon Health & Science University, Protland

02115

Boston Children's Hospital, Boston

All Listed Sponsors
collaborator

Atopic Dermatitis Research Network

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01737710 - Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study | Biotech Hunter | Biotech Hunter